Syrrx, Inc.

Strategic Profile

Syrrx's core competitive advantage was its automated systems for protein structure determination and rational drug discovery targeting validated human clinical trial targets. The company focused on small molecule inhibitors for cancer, metabolic diseases (particularly Type 2 diabetes), and inflammation, with partnerships including Novartis and ongoing DPP IV inhibitor development programs.

Cyborg Score Rationale

Syrrx ceased independent operations following its February 2005 acquisition by Takeda Pharmaceuticals. As a subsidiary, the company's autonomous business metrics and strategic positioning are no longer independently measurable.

Top Insights

• Founded in 1999 with focus on high-throughput X-ray crystallography for structure-guided drug discovery
• Acquired by Takeda in February 2005, becoming Takeda's entry point to US research operations
• Developed proprietary automated systems for protein structure analysis in partnership with Novartis
• Pipeline included Type 2 diabetes and HDAC/HSD1 inhibitor programs at time of acquisition

Recent Developments

• (2005) Acquired by Takeda Pharmaceuticals for $270 million
• (2001) Strategic alliance formed with Novartis Genomics Institute for automated protein structure analysis

Open the full interactive Syrrx, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.